Last reviewed: July 2, 2026
Last updated: July 2, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
When you start semaglutide therapy, your body doesn't shed pounds evenly from every area at once. Clinical observation and patient reports consistently show that fat loss follows a predictable pattern influenced by genetics, metabolism, and how your body stores energy. Understanding where you're likely to lose weight first can help set realistic expectations and stay motivated during your weight loss journey.
Why Face and Midsection Show Change First
The face and abdominal region tend to be the first places where semaglutide users notice visible fat loss. This happens because visceral fat—the metabolically active fat stored around your organs in the belly—responds quickly to appetite suppression and reduced calorie intake. Your face becomes noticeably slimmer within 2-4 weeks for many users, partly because facial fat is distributed across a smaller surface area, making changes more obvious.
Semaglutide works by activating GLP-1 receptors in your brain that control hunger and satiety signals. As you eat less and your body taps into stored energy reserves, the midsection—which often accumulates first during weight gain—tends to release its stores relatively early in treatment. This visceral fat reduction also improves metabolic markers like insulin sensitivity and blood pressure, adding a health benefit beyond appearance.
The Role of Genetics in Your Personal Fat Loss Pattern
Your genetic makeup significantly influences where your body preferentially stores and releases fat. The FTO gene variant (rs9939609) and MC4R receptor genes affect how your body distributes weight and responds to appetite-suppressing medications. Two people starting semaglutide on the same dose may experience completely different fat loss patterns based on these underlying genetic differences.
PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after your first treatment month) to map 14 pathways and 49 peptides related to weight metabolism. Understanding your genetic predispositions helps predict whether you'll lose weight more rapidly from the upper body, lower body, or midsection—enabling your clinical team to set personalized expectations and adjust your treatment strategy if needed.
Timeline for Visible Results in Different Body Areas
Most semaglutide users report noticing facial changes within 2-4 weeks of starting treatment. The belly and waist typically show measurable reduction within 4-8 weeks, as visceral fat mobilizes quickly once calorie intake drops significantly. Legs, hips, and upper arms often take 8-12 weeks or longer to show noticeable change, though the scale may indicate overall loss happening in these areas.
The variation in timeline depends partly on how much weight you need to lose and how your individual metabolism responds to the medication. Someone who needs to lose 30 pounds may see face and midsection changes within a month, while someone targeting 100+ pounds might notice these changes more gradually. Consistency with your semaglutide dose and adherence to healthy eating habits accelerates the overall timeline across all body regions.
Semaglutide Injection for Predictable, Steady Loss
PlexusDx Compounded Semaglutide Injection starts at $149 per month and delivers consistent, subcutaneous dosing that many users find produces the steadiest fat loss pattern. Injected semaglutide reaches peak levels predictably each week, maintaining stable appetite suppression and metabolic changes that translate to reliable changes across all body areas over time. Your dose may need to go up as your body adapts, but your price stays flat—removing barriers to finding your optimal therapeutic dose.
Compounded semaglutide from PlexusDx comes from licensed 503A compounding pharmacies and is available across all 50 states without insurance requirements. HSA and FSA accounts are eligible for payment, making treatment accessible for most patients. The consistent weekly dosing pattern helps your body establish a regular fat loss rhythm, with most users seeing the facial and abdominal changes described above within the first month of treatment.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I lose weight from my face first on semaglutide?
Most users notice facial fat loss within 2-4 weeks of starting semaglutide. The face contains less overall fat mass than the torso or legs, so changes appear visually obvious quickly. This early facial change is one of the most commonly reported early signs that the medication is working.
Why does belly fat disappear before leg or arm fat?
Visceral fat in the abdomen is metabolically active and responds quickly to reduced calorie intake and appetite suppression from semaglutide. Subcutaneous fat in the legs and arms tends to mobilize later in your weight loss journey. Genetics plays a role—your FTO and MC4R genes influence this order specifically.
How much does semaglutide injection cost at PlexusDx?
PlexusDx Compounded Semaglutide Injection starts at $149 per month across all commitment tiers. Your dose may need to go up as your treatment progresses, but your monthly price remains flat. No insurance is required, and HSA/FSA accounts are eligible.
Is compounded semaglutide safe and regulated?
PlexusDx semaglutide comes exclusively from licensed 503A compounding pharmacies, which operate under strict FDA oversight and state pharmacy board regulations. While compounded medications are not FDA-approved, they are legally manufactured under pharmaceutical-grade standards and quality controls.
Can genetic testing predict where I'll lose weight first?
The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes variants in FTO, MC4R, GLP1R, and GIPR genes across 14 pathways and 49 peptides. These insights reveal your genetic predispositions for fat distribution and metabolic response, helping predict your personal weight loss pattern and optimize your treatment plan.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Alleviate Ozempic Side Effects for a Smoother Experience
When Will Ozempic Be Approved for Weight Loss? Understanding Its Role and Future